TD Asset Management Inc Has $4.07 Million Stock Holdings in Rapport Therapeutics, Inc. $RAPP

TD Asset Management Inc trimmed its position in Rapport Therapeutics, Inc. (NASDAQ:RAPP) by 30.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 137,014 shares of the company’s stock after selling 59,856 shares during the quarter. TD Asset Management Inc owned 0.38% of Rapport Therapeutics worth $4,069,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Strs Ohio raised its holdings in shares of Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock worth $62,000 after buying an additional 400 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in Rapport Therapeutics in the third quarter valued at about $143,000. SG Americas Securities LLC acquired a new position in Rapport Therapeutics during the third quarter worth about $186,000. New York State Common Retirement Fund raised its stake in Rapport Therapeutics by 108.6% during the third quarter. New York State Common Retirement Fund now owns 7,300 shares of the company’s stock worth $217,000 after acquiring an additional 3,800 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after acquiring an additional 4,582 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. HC Wainwright raised their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. BTIG Research restated a “buy” rating and set a $47.00 price target on shares of Rapport Therapeutics in a report on Monday, December 8th. Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.80.

Insider Buying and Selling at Rapport Therapeutics

In other news, insider David Bredt sold 8,500 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $29.02, for a total value of $246,670.00. Following the transaction, the insider directly owned 387,075 shares of the company’s stock, valued at $11,232,916.50. The trade was a 2.15% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Abraham Ceesay sold 5,833 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $29.34, for a total value of $171,140.22. Following the sale, the chief executive officer owned 556,247 shares in the company, valued at approximately $16,320,286.98. The trade was a 1.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 67,655 shares of company stock worth $1,941,612. 13.57% of the stock is owned by company insiders.

Rapport Therapeutics Stock Performance

Shares of NASDAQ RAPP opened at $27.85 on Wednesday. The company’s 50 day moving average price is $28.17 and its 200-day moving average price is $26.32. Rapport Therapeutics, Inc. has a 52-week low of $6.43 and a 52-week high of $42.27. The company has a market capitalization of $1.33 billion, a P/E ratio of -10.28 and a beta of 1.51.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.